T1	Participants 348 428	chemotherapy-naive patients with progressive castrate metastatic prostate cancer
T2	Participants 633 811	Between December 2001 and October 2003, 92 patients were enrolled and randomly assigned to treatment with ixabepilone alone (45 patients) or in combination with EMP (47 patients)
